From the **Editor**

Accelerated aging in schizophrenia: Shortened telomeres, mitochondrial dysfunction, inflammation, and oxidative stress



Henry A. Nasrallah, MD Editor-in-Chief

Several lines of evidence are coalescing into a critical scientific insight: Persons with schizophrenia show evidence of accelerated aging.¹

This implies early senescence, segmental aging, and, in young adult patients, premature onset of multi-system medical illnesses associated with aging, including cardiovascular disease, cancer, brain atrophy, and cognitive decline. This might be the real reason why persons with schizophrenia die 25 to 30 years too early, not only because of an unhealthy lifestyle and iatrogenic cardio-metabolic adverse effects.

One of the most consistent observations pointing to accelerated aging in schizophrenia is shortened telomeres.^{2,3} Telomeres are the terminal part of chromosomes (similar to the plastic aglets of shoelaces), which are known to shorten with each cell division because of "end replication losses." Telomeres are measured in lymphocytes, which researchers regard as "windows to the brain" because they reflect brain aging.⁴ One study of lymphocytes in patients with schizophrenia found that they appear to be approximately 25 years older than the lymphocytes of healthy individuals!⁴

Possible causes of accelerated aging

Inflammation. The leading hypothesis for accelerated aging in schizophrenia is based on the inflammatory theory of aging. Schizophrenia has been strongly linked to immune dysregulation and neuroinflammation.5 Other components of the accelerated aging hypothesis include oxidative and nitrosative stress, which is associated with high levels of free radicals, and, importantly, mitochondrial dysfunction that fails to generate antioxidants (glutathione peroxidase, superoxide dismutase, and catalase) that can neutralize free radicals and reverse oxidative stress, as numerous studies have shown.

Clinically, and at a relatively young age, persons with schizophrenia show many physical features consistent with aging,⁶ including the following system changes:

• **CNS**: dilated ventricles, reduced brain volume and gray matter volume; hypofrontality, neurocognitive deficits

At a relatively young age, persons with schizophrenia manifest biological and clinical features consistent with premature aging

To comment on this editorial or other topics of interest, visit www.facebook.com/ CurrentPsychiatry, or go to CurrentPsychiatry.com and click on the "Contact us" link.



Editorial Staff

EDITOR Erica Vonderheid SENIOR EDITOR Patrice Kubik WEB ASSISTANTS Tyler Mundhenk, Kathryn Wighton

Art & Production Staff

CREATIVE DIRECTOR Mary Ellen Niatas ART DIRECTOR Pat Fopma DIRECTOR, JOURNAL MANUFACTURING Michael Wendt PRODUCTION MANAGER Donna Pituras

Publishing Staff

PUBLISHER Sharon J. Spector DIGITAL ACCOUNT MANAGER Reinaldo Valdivia MARKETPLACE ACCOUNT MANAGER Linda Wilson CONFERENCE MARKETING MANAGER Kathy Wenzler

Editor-in-Chief Emeritus James Randolph Hillard, MD

Frontline Medical Communications CHAIRMAN Stephen Stoneburn EVP DIGITAL BUSINESS DEVELOPMENT/CFO Douglas E. Grose PRESIDENT/CEO Alan J. Imhoff PRESIDENT, CUSTOM SOLUTIONS JoAnn Wahl VICE PRESIDENT FINANCE Dennis Quirk VICE PRESIDENT, OPERATIONS Jim Chicca VICE PRESIDENT, AUDIENCE DEVELOPMENT **Donna Sickles** VICE PRESIDENT, CUSTOM PROGRAMS Carol Nathan VICE PRESIDENT, CUSTOM SOLUTIONS Wendy Raupers VICE PRESIDENT, eBUSINESS DEVELOPMENT Lee Schweizer VICE PRESIDENT, HUMAN RESOURCES

& FACILITY OPERATIONS Carolyn Caccavelli VICE PRESIDENT, MARKETING & CUSTOMER ADVOCACY Jim McDonough

VICE PRESIDENT, SALES Mike Guire VICE PRESIDENT, SOCIETY PARTNERS Mark Branca

CORPORATE DIRECTOR, RESEARCH & COMMUNICATIONS Lori Raskin

EDITORIAL DIRECTOR Karen J. Clemments

Subscription Services: (800) 480-4851 In affiliation with Global Academy for Medical Education, LLC VICE PRESIDENT, MEDICAL EDUCATION & CONFERENCES Sylvia H. Reitman, MBA VICE PRESIDENT, EVENTS David J. Small, MBA



7 Century Drive, Suite 302 Parsippany, NJ 07054 Tel: (973) 206-3434 Fax: (973) 206-9378 www.frontlinemedcom.com

Published through an educational partnership with Saint Louis University



Saint Louis Universit

From the **Editor**

such as executive functioning, working memory, and attention; neurophysiologic (low amplitudes on evoked potentials)

• Musculoskeletal system: abnormalities in muscle fibers; altered nerve conduction velocity; reduced bone density

• Skin: aging skin

• Eyes: increased rate of cataracts (not caused by medications); degradation in motion discrimination

• Endocrine system: abnormal gonadal hormones; low estrogen; low androgen; thyroid dysfunction, elevated cortisol

• Metabolism: increased rates of obesity; glucose dysregulation even before antipsychotic treatment; increased insulin resistance; abnormal glucose tolerance; reduced insulin-like growth factor-1 levels

• Immune system: increased proinflammatory cytokines (interleukin [IL]-1B, IL-6, IL-3, IL-4, IL-10, IL-13, tumor necrosis factor- α) and decrease in anti-inflammatory cytokines (IL-2, interferon [INF]- α , INF- γ) and vitamin D

• **Cardiovascular**: systolic hypertension, increased pulse pressure

• Oxidative stress and mitochondrial dysfunction: increase in reactive oxygen species in brain tissue and increased DNA and RNA oxidation markers

• **Telomere dynamics**: significantly higher rates of telomere loss.

The mitochondrial theory of aging.7

The origin of this theory dates back to the landmark work of Denham Harman more than 2 decades ago in which he proposed a connection between free radicals and aging, which is associated with cell mutations and cancer.⁸ He suggested that because mitochondrial DNA is not protected by histones as DNA in the nucleus is, it might be the main target for free radicals, making the mitochondria more susceptible to oxidative damage. Therefore, it is possible that the high oxidative stress of schizophrenia could contribute to mitochondrial dysfunction, which leads to further telomere erosion.⁹ Perhaps reducing oxidative stress in schizophrenia with a powerful antioxidant, such as the supplement *N*-acetylcysteine,¹⁰ could help repair the dysfunctional mitochondria found in patients with schizophrenia and might mitigate accelerated aging.

I would like to propose a bolder, even radical, "out-of-the-box" therapeutic strategy for accelerated aging: mitochondrial transplantation. In fact, "mitochondrial donation" and transplant has been performed on fetuses with genetically defective mitochondria, which has prevented rapid death after birth.¹¹

Similarities with progeria. The accumulating evidence for accelerated aging in schizophrenia has promoted some researchers to consider it a form of progeria¹² because of the accelerated aging features that patients with schizophrenia manifest. Patients with schizophrenia share some risk factors with patients with progeria, including high paternal age, prenatal stress, prenatal famine, low birth weight, and premature cognitive decline. Both progeria and schizophrenia are associated with increased apoptosis and cell senescence, which could reduce the risk of cancer but result in premature aging along with age-related medical disorders that lead to mortality in the elderly.

This is why collaborative care between psychiatrists and primary care providers is so vital for patients with schizophrenia from the onset of the illness during the teens and young adulthood, not after years of treatment and unhealthy lifestyle habits (smoking, sedentary living, high-fat and

22 Current Psychia November 2016 high-calorie diet), which add insult to injury, culminating in loss of 25 to 30 years of potential life. Preventative medical care starting when schizophrenia is first diagnosed is vital, in addition to comprehensive psychiatric care, because premature mortality is the worst outcome in medicine.

Nanallal

Henry A. Nasrallah, MD Editor-in-Chief

References

- Kirkpatrick B, Messias E, Harvey PD, et al. Schizophrenia as a syndrome of accelerated aging? Schizophr Bull. 2005;34(6):1024-1032.
- Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008;88(2):557-579.

- Kao HT, Cawthon RM, Delisi LE, et al. Rapid telomere erosion in schizophrenia. Mol Psychiatry. 2008;13(2):118-119.
- Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probes: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):559-576.
- Horváth S, Mirnics K. Immune system disturbance in schizophrenia. Biol Psychiatry. 2014;75(4):316-323.
- Shirakumar V, Kalmady SV, Venkatasubramanian G, et al. Do schizophrenia patients age early? Asian J Psychiatr. 2014;10:3-9.
- Passos JF, von Zglinicki T. Mitochondria, telomeres and cell senescence. Exp Gerontol. 2005;40(6):466-472.
- Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1992;20(4):145-147.
- von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2000;27(7):339-344.
- Chen AT, Chibnall JT, Nasrallah HA. A systematic review of placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: a review. Ann Clin Psychiatry. 2016;28(3):190-196.
- 11. Three's company. The Economist. July 9, 2016:88.
- 12. Papanastasiov E, Gaughran F, Smith S. Schizophrenia as segmental progeria. J R Soc Med. 2011;104(11): 475-484.

Preventative medical care starting when schizophrenia is first diagnosed is vital because premature mortality is the worst outcome in medicine

😃 🖹 Now online and in print

CLINICAL EXPERTS IN BIPOLAR DEPRESSION

Exploring Collaborative Care

Clinical Expert faculty from 5 regions of the U.S. comment on the management of patients with bipolar depression.

As healthcare systems change to become more patient centered, patients with bipolar disorder may benefit from integrated care delivery models.

A panel of **Clinical Expert** faculty provides firsthand knowledge and insights into a collaborative care approach to the diagnosis and treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression).

Find out how psychiatrists and other healthcare professionals in your region of the United States are collaborating with each other to improve care for patients with bipolar depression.



The promotional, non-CME content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder.

©2016 Sunovion Pharmaceuticals Inc. All rights reserved. 04/16 LAT119-16